Genelux (NASDAQ:GNLX) (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.
Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents. Preclinical work has also been directed at optimizing dosing regimens and delivery methods to maximize oncolytic activity and immune priming. The company conducts its clinical development programs in collaboration with academic medical centers and research hospitals across North America and Europe, ensuring access to patient populations in regions with high unmet need.
Originally founded as a private research entity, Genelux completed its transition to a publicly traded company in January 2021, listing its common stock on the Nasdaq Global Market under the ticker symbol GNLX. Headquartered in Richmond, Virginia, the company maintains research and administrative operations in the United States, while engaging with contract development and manufacturing organizations (CDMOs) to support viral vector production and scale-up activities.
Genelux’s leadership team is led by Michael P. Sherman, M.D., J.D., who serves as President and Chief Executive Officer. Dr. Sherman brings extensive experience in oncology drug development, regulatory affairs and corporate financing. Under his direction, Genelux is advancing its oncolytic immunotherapy platform with the goal of delivering novel, broadly applicable treatments to patients with refractory solid tumors.
